Attached files
| file | filename |
|---|---|
| EX-99.1 - EX-99.1 - Paratek Pharmaceuticals, Inc. | prtk-ex991_6.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
December 3, 2018
Date of Report (Date of earliest event reported)
PARATEK PHARMACEUTICALS, INC.
(Exact name of Registrant as specified in its charter)
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware |
|
001-36066 |
|
33-0960223 |
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer Identification No.) |
|
|
|
|||
|
75 Park Plaza Boston, MA |
|
02116 |
||
|
(Address of principal executive offices) |
|
(Zip Code) |
||
(617) 807-6600
(Registrant’s telephone number, including area code)
Not applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
|
|
|
|
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
|
|
|
|
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
|
|
|
|
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (230.405 of this chapter) or Rule 12b-2of the Securities Exchange Act of 1934 (§ 240 12b-2 of this chapter).
Emerging Growth Company ☐
If an emerging growth company, indicate by a check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 7.01 Regulation FD Disclosure.
On December 3, 2018, Paratek Pharmaceuticals, Inc. issued a press release announcing that it filed two patent term extension requests with the U.S. Patent and Trademark Office for patents covering NUZYRA™ (omadacycline), including for U.S. Patent No. 7,553,828, directed to composition of matter, and U.S. Patent No. 9,265,740, directed to a method of treatment.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
The information in this report (including Exhibit 99.1) is being furnished pursuant to Item 7.01 and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor will it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or in any filing under the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
|
|
|
|
|
|
|
|
Number |
|
Description |
|
|
|
|
|
|
|
|
|
99.1 |
|
Paratek Pharmaceuticals, Inc. Press Release dated December 3, 2018 |
|
|
|
|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
Date: December 3, 2018 |
|
|
|
PARATEK PHARMACEUTICALS, INC. |
||
|
|
|
|
|
|||
|
|
|
|
|
By: |
|
/s/ William M. Haskel |
|
|
|
|
|
|||
|
|
|
|
|
|
|
Name: William M. Haskel |
|
|
|
|
|
|
|
Title: Senior Vice President, General Counsel and Corporate Secretary |